# Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

> **NCT02446093** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Candel Therapeutics, Inc.** · enrollment: 54 (estimated)

## Conditions studied

- Borderline Resectable Pancreatic Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Aglatimagene besadenovec
- **RADIATION:** Chemoradiation
- **RADIATION:** Stereotactic body radiation therapy
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT02446093
- **Lead sponsor:** Candel Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10
- **Primary completion:** 2025-12
- **Final completion:** 2026-07
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446093, "Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02446093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*